170 related articles for article (PubMed ID: 22688849)
1. Reduction in Hepatic Inflammation Is Associated With Less Fibrosis Progression and Fewer Clinical Outcomes in Advanced Hepatitis C.
Morishima C; Shiffman ML; Dienstag JL; Lindsay KL; Szabo G; Everson GT; Lok AS; Di Bisceglie AM; Ghany MG; Naishadham D; Morgan TR; Wright EC;
Am J Gastroenterol; 2012 Sep; 107(9):1388-98. PubMed ID: 22688849
[TBL] [Abstract][Full Text] [Related]
2. Effect of HCV RNA suppression during peginterferon alfa-2a maintenance therapy on clinical outcomes in the HALT-C trial.
Shiffman ML; Morishima C; Dienstag JL; Lindsay KL; Hoefs JC; Lee WM; Wright EC; Naishadham D; Everson GT; Lok AS; Di Bisceglie AM; Bonkovsky HL; Ghany MG;
Gastroenterology; 2009 Dec; 137(6):1986-94. PubMed ID: 19747918
[TBL] [Abstract][Full Text] [Related]
3. Prolonged therapy of advanced chronic hepatitis C with low-dose peginterferon.
Di Bisceglie AM; Shiffman ML; Everson GT; Lindsay KL; Everhart JE; Wright EC; Lee WM; Lok AS; Bonkovsky HL; Morgan TR; Ghany MG; Morishima C; Snow KK; Dienstag JL;
N Engl J Med; 2008 Dec; 359(23):2429-41. PubMed ID: 19052125
[TBL] [Abstract][Full Text] [Related]
4. Long-term histological change in chronic hepatitis C patients who had received peginterferon plus ribavirin therapy with sustained virological response.
Chu CY; Cheng CH; Chen HL; Lin IT; Wu CH; Lee YK; Bair MJ
J Formos Med Assoc; 2019 Jul; 118(7):1129-1137. PubMed ID: 30472042
[TBL] [Abstract][Full Text] [Related]
5. Impact of fibrosis progression on clinical outcome in patients treated for post-transplant hepatitis C recurrence.
Dhanasekaran R; Sanchez W; Mounajjed T; Wiesner RH; Watt KD; Charlton MR
Liver Int; 2015 Nov; 35(11):2433-41. PubMed ID: 26058570
[TBL] [Abstract][Full Text] [Related]
6. Rate of progression of hepatic fibrosis in patients with chronic hepatitis C: results from the HALT-C Trial.
Hoefs JC; Shiffman ML; Goodman ZD; Kleiner DE; Dienstag JL; Stoddard AM;
Gastroenterology; 2011 Sep; 141(3):900-908.e1-2. PubMed ID: 21699796
[TBL] [Abstract][Full Text] [Related]
7. Impact of disease severity on outcome of antiviral therapy for chronic hepatitis C: Lessons from the HALT-C trial.
Everson GT; Hoefs JC; Seeff LB; Bonkovsky HL; Naishadham D; Shiffman ML; Kahn JA; Lok AS; Di Bisceglie AM; Lee WM; Dienstag JL; Ghany MG; Morishima C;
Hepatology; 2006 Dec; 44(6):1675-84. PubMed ID: 17133499
[TBL] [Abstract][Full Text] [Related]
8. Durability of the response to peginterferon-α2b and ribavirin in patients with chronic hepatitis C: a cohort study in the routine clinical setting.
Giordanino C; Sacco M; Ceretto S; Smedile A; Ciancio A; Cariti G; De Blasi T; Picciotto A; Marenco S; Grasso A; Pirisi M; Smirne C; Colletta C; Traverso A; Mazzucco D; Ciccone G; Simondi D; Rizzetto M; Saracco G
Eur J Gastroenterol Hepatol; 2014 Jan; 26(1):52-8. PubMed ID: 23719564
[TBL] [Abstract][Full Text] [Related]
9. Hepatic fibrosis and serum alpha-fetoprotein (AFP) as predictors of response to HCV treatment and factors associated with serum AFP normalisation after treatment.
El Raziky M; Attia D; El Akel W; Shaker O; Khatab H; Abdo S; Elsharkawy A; Esmat G
Arab J Gastroenterol; 2013 Sep; 14(3):94-8. PubMed ID: 24206736
[TBL] [Abstract][Full Text] [Related]
10. Durability of a sustained virological response, late clinical sequelae, and long-term changes in aspartate aminotransferase to the platelet ratio index after successful treatment with peginterferon/ribavirin for chronic hepatitis C: a prospective study.
Papastergiou V; Stampori M; Lisgos P; Pselas C; Prodromidou K; Karatapanis S
Eur J Gastroenterol Hepatol; 2013 Jul; 25(7):798-805. PubMed ID: 23395996
[TBL] [Abstract][Full Text] [Related]
11. Antiviral therapy and fibrosis progression in patients with mild-moderate hepatitis C recurrence after liver transplantation. A randomized controlled study.
Belli LS; Volpes R; Graziadei I; Fagiuoli S; Starkel P; Burra P; Alberti AB; Gridelli B; Vogel W; Pasulo L; De Martin E; Guido M; De Carlis L; Lerut J; Cillo U; Burroughs AK; Pinzello G
Dig Liver Dis; 2012 Jul; 44(7):603-9. PubMed ID: 22424641
[TBL] [Abstract][Full Text] [Related]
12. Peginterferon α-2a plus ribavirin in Latino and Non-Latino Whites with HCV genotype 1: Histologic outcomes and tolerability from the LATINO Study.
Balart LA; Lisker-Melman M; Hamzeh FM; Kwok A; Lentz E; Rodriguez-Torres M;
Am J Gastroenterol; 2010 Oct; 105(10):2177-85. PubMed ID: 20389293
[TBL] [Abstract][Full Text] [Related]
13. Peginterferon alfa and ribavirin for chronic hepatitis C in patients eligible for shortened treatment, re-treatment or in HCV/HIV co-infection: a systematic review and economic evaluation.
Hartwell D; Jones J; Baxter L; Shepherd J
Health Technol Assess; 2011 Apr; 15(17):i-xii, 1-210. PubMed ID: 21473834
[TBL] [Abstract][Full Text] [Related]
14. Long-term therapy of chronic delta hepatitis with peginterferon alfa.
Heller T; Rotman Y; Koh C; Clark S; Haynes-Williams V; Chang R; McBurney R; Schmid P; Albrecht J; Kleiner DE; Ghany MG; Liang TJ; Hoofnagle JH
Aliment Pharmacol Ther; 2014 Jul; 40(1):93-104. PubMed ID: 24815494
[TBL] [Abstract][Full Text] [Related]
15. Early virological response in 1220 patients with HCV (genotype lb) chronic hepatitis and cirrhosis treated with PegInterferon plus Ribavirin.
Pascu O; Voiculescu M; Gheorghe L; Micu L; Seicean A; Iliescu L; Mocan T; Ceauşu E; Mateescu B
Rom J Intern Med; 2011; 49(2):105-12. PubMed ID: 22303601
[TBL] [Abstract][Full Text] [Related]
16. Evolution of hepatic steatosis in patients with advanced hepatitis C: results from the hepatitis C antiviral long-term treatment against cirrhosis (HALT-C) trial.
Lok AS; Everhart JE; Chung RT; Kim HY; Everson GT; Hoefs JC; Greenson JK; Sterling RK; Lindsay KL; Lee WM; Di Bisceglie AM; Bonkovsky HL; Ghany MG; Morishima C;
Hepatology; 2009 Jun; 49(6):1828-37. PubMed ID: 19291787
[TBL] [Abstract][Full Text] [Related]
17. Eltrombopag increases platelet numbers in thrombocytopenic patients with HCV infection and cirrhosis, allowing for effective antiviral therapy.
Afdhal NH; Dusheiko GM; Giannini EG; Chen PJ; Han KH; Mohsin A; Rodriguez-Torres M; Rugina S; Bakulin I; Lawitz E; Shiffman ML; Tayyab GU; Poordad F; Kamel YM; Brainsky A; Geib J; Vasey SY; Patwardhan R; Campbell FM; Theodore D
Gastroenterology; 2014 Feb; 146(2):442-52.e1. PubMed ID: 24126097
[TBL] [Abstract][Full Text] [Related]
18. Randomized, double-blind, placebo-controlled study of peginterferon alfa-2a (40KD) plus ribavirin with or without amantadine in treatment-naïve patients with chronic hepatitis C genotype 1 infection.
Ferenci P; Formann E; Laferl H; Gschwantler M; Hackl F; Brunner H; Hubmann R; Datz C; Stauber R; Steindl-Munda P; Kessler HH; Klingler A; Gangl A;
J Hepatol; 2006 Feb; 44(2):275-82. PubMed ID: 16338019
[TBL] [Abstract][Full Text] [Related]
19. Serum fibrosis marker levels decrease after successful antiviral treatment in chronic hepatitis C patients with advanced fibrosis.
Fontana RJ; Bonkovsky HL; Naishadham D; Dienstag JL; Sterling RK; Lok AS; Su GL;
Clin Gastroenterol Hepatol; 2009 Feb; 7(2):219-26. PubMed ID: 19068241
[TBL] [Abstract][Full Text] [Related]
20. Serum fibrosis markers are associated with liver disease progression in non-responder patients with chronic hepatitis C.
Fontana RJ; Dienstag JL; Bonkovsky HL; Sterling RK; Naishadham D; Goodman ZD; Lok AS; Wright EC; Su GL;
Gut; 2010 Oct; 59(10):1401-9. PubMed ID: 20675691
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
